Johannes Drach
Vienna, Austria
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
Journal: The Lancet. Oncology
Published: August 02, 2018
Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized, phase 3 LYM-3002 study.
Journal: Leukemia & lymphoma
Published: January 18, 2018
Serum and urinary levels of CD222 in cancer: origin and diagnostic value.
Journal: Neoplasma
Published: December 03, 2017
Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma.
Journal: American journal of hematology
Published: June 22, 2017
Gender-Specific Aspects in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation: A Single-Center Experience.
Journal: Oncology
Published: April 18, 2017
Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study.
Journal: Haematologica
Published: August 25, 2016
Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study.
Journal: British journal of haematology
Published: August 03, 2016
A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS).
Journal: Leukemia
Published: January 07, 2016
Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality.
Journal: Heart (British Cardiac Society)
Published: March 20, 2015
Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.
Journal: The New England journal of medicine
Published: March 05, 2015
Longer-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL-001(EMERGE) pivotal trial.
Journal: British journal of haematology
Published: December 15, 2014
Last Updated: 09/26/2026